Living Cell Technologies Limited
LVCLY · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $0 | $42 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | $42 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | – | $405 | $379 | $931 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $1,096 | $440 | $380 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $1,501 | $819 | $1,311 |
| Operating Income | – | -$1,501 | -$819 | -$1,311 |
| % Margin | – | – | -1,948.7% | – |
| Other Income/Exp. Net | – | -$302 | -$464 | -$376 |
| Pre-Tax Income | – | -$1,451 | -$801 | -$1,307 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | – | -$1,451 | -$801 | -$1,307 |
| % Margin | – | – | -1,906.7% | – |
| EPS | – | -0.009 | -0.005 | -0.01 |
| % Growth | – | -80% | 50% | – |
| EPS Diluted | – | -0.009 | -0.005 | -0.01 |
| Weighted Avg Shares Out | – | 163,979 | 146,124 | 130,143 |
| Weighted Avg Shares Out Dil | – | 163,979 | 146,124 | 130,143 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $51 | $34 | $8 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $1 | $122 |
| EBITDA | – | -$1,149 | -$337 | -$930 |
| % Margin | – | – | -801.4% | – |